KAGAWA, Japan – June 21, 2022 – MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technology to lead life science innovation, has partnered with Taniguchi Dental Clinics to strengthen genomic research and sequencing capabilities in Japan.
Mr. Taniguchi, founder and head of the Oral Microbiome Centre at Taniguchi Dental Clinics, also leads three organizations — the Oral Microbiome Centre, Taniguchi Dental Clinic, and Genome Lead, a sequencing service provider based in Kagawa Prefecture. Since 2014, he has been devoted to studying and analysing the human oral microbiota to improve dental care and disease prevention through personalized treatment strategies.
To date, Mr. Taniguchi has conducted more than 5,000 oral flora 16S rRNA metagenomic analyses using next-generation sequencing. His work also extends to studying microbial communities in other body sites, such as the intestines, skin, and endometrium, as well as environmental samples including fish and soil. He has also contributed to a large-scale intestinal microbiota analysis project led by a local medical university, analysing several thousand samples.
In 2021, Mr. Taniguchi established Genome Lead, an independent entity providing high-quality NGS services across microbiome analysis, whole genome sequencing (WGS), whole exome sequencing (WES), and RNA sequencing (RNA-Seq) for universities, hospitals, research institutions, and commercial clients.
Partnering with MGI
As the founder of Genome Lead, Mr. Taniguchi recognized that many clients required high-throughput sequencing solutions that were previously limited by cost and accessibility. To address this challenge, he adopted MGI’s DNBSEQ™ platforms, which offer faster, more affordable sequencing with exceptional accuracy and flexibility.
“MGI provides not only cost-effective solutions but also outstanding after-sales support,” said Mr. Taniguchi. “Their technology helps us meet diverse sequencing needs with flexibility and efficiency.”
MGI’s DNBSEQ-G400 sequencer* allows configuration flexibility through interchangeable flow cell types — from FCL (4 lanes) to FCS (2 lanes) — to accommodate various throughput requirements. As DNBSEQ technology gains recognition in Japan, demand for DNBSEQ-designated sequencing is rapidly increasing.
With the introduction of the DNBSEQ-T7* and MGI’s automation systems (MGISP-100, MGISP-960), Genome Lead now achieves high-efficiency sequencing with minimal hands-on time. The DNBSEQ-T7 can generate up to 6 terabases (Tb) per day, offering exceptional throughput and flexibility with four independently operated flow cells. Mr. Taniguchi highlighted the systems’ accuracy, reproducibility, and scalability as key advantages for his laboratory.
Moving Forward
Today, Mr. Taniguchi leads one of Japan’s most advanced sequencing laboratories, offering customized genomic services tailored to diverse client needs. He credits MGI as a critical long-term partner supporting his mission to deliver reliable, high-performance sequencing.
“Selecting the right partner is essential,” Mr. Taniguchi noted. “MGI has become one of the most important partners for us, and we look forward to continuing our collaboration to advance Japan’s genome research market.”
About Taniguchi Dental Clinics
Founded in 2014, Taniguchi Dental Clinics specializes in oral microbiome analysis using high-throughput sequencing technology. The clinic studies the relationship between oral bacteria and overall health, providing preventive and personalized treatment based on individual microbiota profiles. Its services include microbial genome analysis for clinical research, hospitals, and academic institutions.
Disclaimer
Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents, are not available in Germany, the USA, Spain, the UK, Hong Kong, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal, Austria, and Romania.
